Alector Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alector in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Alector stock.
View analyst ratings for Alector or view top-rated stocks.

Wall Street analysts have given Alector a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Alector wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Alector is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Alector.

Alector, Inc. (NASDAQ:ALEC) issued its quarterly earnings data on Tuesday, May, 4th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.69) by $0.03. Alector had a negative trailing twelve-month return on equity of 69.73% and a negative net margin of 1,122.03%.
View Alector's earnings history.

Alector's stock was trading at $24.92 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALEC stock has decreased by 21.3% and is now trading at $19.62.
View which stocks have been most impacted by COVID-19.

4 brokerages have issued 1-year target prices for Alector's shares. Their forecasts range from $31.00 to $41.00. On average, they anticipate Alector's share price to reach $34.40 in the next twelve months. This suggests a possible upside of 75.3% from the stock's current price.
View analysts' price targets for Alector or view top-rated stocks among Wall Street analysts.

4 employees have rated Alector CEO Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among Alector's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Alector include Vir Biotechnology (VIR), Halozyme Therapeutics (HALO), Beam Therapeutics (BEAM), Twist Bioscience (TWST), Adaptive Biotechnologies (ADPT), Recursion Pharmaceuticals (RXRX), Sana Biotechnology (SANA), Abcam (ABCM), SpringWorks Therapeutics (SWTX), Kodiak Sciences (KOD), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Relay Therapeutics (RLAY) and BioCryst Pharmaceuticals (BCRX).
View all of ALEC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).

(ALEC) raised $177 million in an IPO on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.

Alector trades on the NASDAQ under the ticker symbol "ALEC."

Alector's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.62%), Federated Hermes Inc. (5.82%), Franklin Resources Inc. (4.08%), Price T Rowe Associates Inc. MD (3.38%), JPMorgan Chase & Co. (3.28%) and Gilder Gagnon Howe & Co. LLC (2.30%). Company insiders that own Alector stock include Calvin Yu, David M Wehner, Orbimed Advisors Llc, Robert King, Robert Paul, Sabah Oney and Terrance Mcguire.
View institutional ownership trends for Alector.

ALEC stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Gilder Gagnon Howe & Co. LLC, Integral Health Asset Management LLC, Credit Suisse AG, Squarepoint Ops LLC, Millennium Management LLC, PDT Partners LLC, and Northern Trust Corp. Company insiders that have sold Alector company stock in the last year include Calvin Yu, Robert Paul, and Terrance Mcguire.
View insider buying and selling activity for Alector or view top insider-selling stocks.

ALEC stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Morgan Stanley, EcoR1 Capital LLC, Pier Capital LLC, Federated Hermes Inc., Ikarian Capital LLC, Dimensional Fund Advisors LP, and Citigroup Inc..
View insider buying and selling activity for Alector or or view top insider-buying stocks.

Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALEC stock can currently be purchased for approximately $19.62.

Alector has a market capitalization of $1.57 billion and generates $21.10 million in revenue each year. The company earns $-190,230,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis.

Alector employs 171 workers across the globe.

The official website for Alector is www.alector.com.

Alector is headquartered at 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080.

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]